What is Somahlution?
Somahlution, operating under the umbrella of Marizyme Inc, is a specialized biotechnology enterprise dedicated to advancing cardiac surgery outcomes. The company is best known for its proprietary DuraGraft Technology, which serves as the inaugural FDA-cleared solution for the preservation and storage of saphenous vein grafts during Coronary Artery Bypass Grafting (CABG). By mitigating oxidative stress and preserving cellular integrity, the firm provides a critical alternative to conventional saline storage methods. This technological edge positions Somahlution as a vital partner for healthcare institutions seeking to improve long-term patient outcomes in complex cardiovascular procedures.
How much funding has Somahlution raised?
Somahlution has raised a total of $150K across 1 funding round:
Debt
$150K
Debt (2020): $150K with participation from PPP
Key Investors in Somahlution
PPP
Public-Private Partnership
What's next for Somahlution?
Following this late-stage financing, Somahlution is expected to prioritize the scaling of its commercial operations and the expansion of its market footprint within the global cardiac surgery sector. The strategic deployment of this capital will likely focus on enhancing distribution networks and supporting clinical adoption of the DuraGraft platform. As the company transitions into this growth phase, stakeholders will be monitoring its ability to capture additional market share from traditional storage methodologies, thereby solidifying its role as a leader in surgical graft preservation and medical innovation.
See full Somahlution company page
